MED3000 (Eroxon®) European Patent Opposition
Futura Medical plc announced that the European Patent Office Opposition Division has decided to revoke European Patent No. EP 3934624B1 for MED3000 (Eroxon®), a decision the company intends to appeal to the EPO Technical Board of Appeal, a process expected to take 18 to 24 months. Importantly, the patent remains in force during the appeal, and this decision does not impact current commercial arrangements, the continued sale of Eroxon®, or the company's ability to supply customers, nor does it affect other patents in Futura's intellectual property portfolio.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
Futura Medical announces that the European Patent Office ("EPO") Opposition Division has issued its written decision confirming the revocation of European Patent No. EP 3934624B1 for MED3000 (Eroxon®), following the Oral Hearing held on 8 May 2026.
The Company disagrees with the Opposition Division's decision, which it believes does not appropriately reflect fundamental principles of clinical research and development, and therefore intends to appeal the decision to the EPO Technical Board of Appeal. According to legal advice received by the Company, a full appeal process typically takes between 18 and 24 months, or longer, to conclude.
Importantly, the patent protection provided by EP 3934624B1 remains in force while the appeal is pending. The decision also does not affect the Company's existing commercial arrangements, the continued commercialisation of Eroxon®, or the Company's ability to continue supplying customers under those arrangements.
The decision relates solely to European Patent No. EP 3934624B1 and does not directly affect any other granted or pending patents within Futura's intellectual property portfolio including patents in other territories, the Company's European divisional patent application for MED3000, which is currently under examination, and separate patent filings relating to WSD4000, Futura's topical gel for the treatment of female sexual dysfunction.
Futura remains committed to protecting and defending its intellectual property portfolio globally and will continue to pursue all appropriate steps to safeguard its proprietary technologies.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.